Financial Review: Nyxoah (NASDAQ:NYXH) versus Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ)

Nyxoah (NASDAQ:NYXH) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations and institutional ownership.

Insider and Institutional Ownership

89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. 17.1% of Nyxoah shares are held by company insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and price targets for Nyxoah and Health Sciences Acquisitions Co. 2, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	0	0	5	0	3.00
Health Sciences Acquisitions Co. 2	0	0	0	0	0.00

Nyxoah presently has a consensus target price of $17.00, suggesting a potential upside of 69.32%. Given Nyxoah’s stronger consensus rating and higher possible upside, equities analysts clearly believe Nyxoah is more favorable than Health Sciences Acquisitions Co. 2.

Earnings & Valuation

This table compares Nyxoah and Health Sciences Acquisitions Co. 2″s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$5.08 million	67.29	-$46.77 million	($1.87)	-5.37
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380,000.00	N/A	N/A

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Nyxoah.

Risk & Volatility

Nyxoah has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, indicating that its share price is 91% less volatile than the S&P 500.

Profitability

This table compares Nyxoah and Health Sciences Acquisitions Co. 2’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nyxoah	-1,043.93%	-51.68%	-40.11%
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%

Summary

Health Sciences Acquisitions Co. 2 beats Nyxoah on 6 of the 11 factors compared between the two stocks.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

About Health Sciences Acquisitions Co. 2

Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.